HUHasan Huseyin Uckan

Hasan Huseyin Uckan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hasan Huseyin Uckan has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The analysis of pregnancies terminated before and after the limit of viability: A medicolegal view

    by Cem Terece, Gokce Turan, Hasan Hüseyin Uckan, Ayla Eser, Mustafa Rasit Ozler, Suheda Gunbay, Mehmet Zeki Taner


  • Open Access

    Evaluation of androgen-dependent skin findings of polycystic ovary syndrome (PCOS)

    by Gokhan Artar, Betul Tas, Gokce Turan, Hasan Huseyin Uckan

    The purpose of the study was to investigate the biochemical and metabolic abnormalities related to the cutaneous characteristics of PCOS.Patients diagnosed with PCOS were included in the study. Dem...


  • Congenital central nervous system anomalies: Ten-year single center experience on a challenging issue in perinatal medicine

    by Emine Aydın, Atakan Tanacan, Melek Büyükeren, Hasan Uçkan, Murat Yurdakök, Mehmet Sinan Beksaç

    Objective: Our goal was to highlight the prenatal diagnosis and management of central nervous system (CNS) anomalies through sharing our clinic's experience. Methods: We evaluated prenatal findings and postnatal outcomes of neonates who had a CNS anomaly diagnosis in our clinic over a ten-year period. A total of 183 cases with various CNS anomalies were included in the study. Birth or termination preferences of mothers were recorded in all cases, and postnatal diagnosis concordance and prognosis after surgical procedures were evaluated in mothers who chose to continue the pregnancy. Results: The mean maternal age was 28.2 +/- 5.5 years, mean gravida was 2.2 +/- 1.3, and the mean gestational age at diagnosis was 30.5 +/- 5.5 weeks. Seventy-five out of 183 (41%) patients chose to terminate their pregnancy. Twenty babies (26.6%) in the termination of pregnancy group had additional anomalies. One hundred eight patients gave birth at our institution. The mean birth weight was 3060 +/- 647.5 g, the mean gestational week at delivery was 37.9 +/- 1.7 weeks, and mean APGAR score (5th minute) was 8.8 +/- 2.3. Four neonates died on the postpartum first day. The postnatal diagnosis of 60 of the 108 (55.5%) patients who gave birth was concordant with the prenatal diagnosis, and 32 of the 108 (29.6%) babies underwent surgical interventions. Conclusion: CNS anomalies have a broad spectrum and variable prognoses. This study highlights the limitations of prenatal diagnoses, and the need for parents to have this information in order to determine the course of their pregnancy and prepare themselves for the postnatal challenging treatment/rehabilitation process.


  • What is the impact of stromal microinvasion on oncologic outcomes in borderline ovarian tumors? A multicenter case–control study

    by Gokhan Boyraz, Mehmet Coskun Salman, Murat Gultekin, Nazlı Topfedaisi Ozkan, Hasan H. Uckan, Kemal Gungorduk, Varol Gulseren, Hulya Ayik, Tayfun Toptas, Oguzhan Kuru, et al.

    Purpose To investigate clinicopathological characteristics and oncological outcome of women with microinvasive BOTs. Methods A retrospective multicenter case–control study was conducted on 902 patients with BOT, who underwent surgery from January 2002 to December 2015 at six participating gynecologic oncology centers from Turkey. Among 902 patients, 69 had microinvasive BOT. For every patient with microinvasive BOT, two controls were randomly selected from another database based on decade of age and stage of disease at diagnosis. The clinical–pathological characteristics and oncological outcomes were compared between BOT patients with and without stromal microinvasion. Risk factors for poor oncological outcomes were investigated in a multivariate analysis model. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan–Meier method. Results Patients with microinvasive BOT had a significantly higher rate of recurrence than patients without microinvasive BOT (17.4 vs 7.8%, OR 3.55, %95 CI 1.091–11.59, p = 0.03). Stage at diagnosis (stage I versus II/III) and type of surgery (cystectomy versus others) were found as other significant prognostic factors for recurrence in multivariate analysis (OR 8.63, %95 CI 2.48–29.9, p = 0.001 and OR 19.4, %95 CI 3.59–105.6, p = 0.001, respectively). Stromal microinvasion was found as a prognostic factor for significantly shorter DFS (26.7 vs 11.9 months, p = 0.031, log rank). However, there was no significant difference in OS between two groups (p = 0.99, log rank). Conclusion Stromal microinvasion is significantly associated with decreased DFS. In addition, our study confirms that the risk of recurrence is higher in patients with microinvasive BOT.